查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1990216

DNA修復药物市场：2026-2032年全球市场预测（依药物类别、作用机制、适应症、给药途径及最终用户划分）

DNA Repair Drugs Market by Drug Class, Mechanism Of Action, Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

DNA修復疗法市场预计到2025年将达到98.7亿美元，到2026年将成长到105.3亿美元，到2032年将达到163.1亿美元，复合年增长率为7.43%。

主要市场统计数据
基准年 2025 98.7亿美元
预计年份：2026年 105.3亿美元
预测年份 2032 163.1亿美元
复合年增长率 (%) 7.43%

全面概述了现代肿瘤学中DNA修復疗法的科学进展、法规环境和商业性需求。

DNA修復疗法领域融合了分子生物学、精准肿瘤学和新型药物技术，共同重塑了多种肿瘤的治疗方法。近年来，随着对肿瘤基因组学和合成致死机制的深入理解，靶向DNA损害反应路径的治疗方法已从学术研究发展成为特定适应症的临床常用疗法。目前，该领域既包括已开发的药物类别，也包括利用癌细胞新发现的脆弱性而研发的新型抑制剂。

基因组精准医疗、适应性临床试验和联合策略如何重塑 DNA 修復疗法的研发重点和商业模式。

DNA修復疗法生态系统正经历变革性的变化，这些变化正在改变研发重点、临床试验设计和商业模式。基因组分析和生物标记检验的进步迫使研发人员设计分子选择性和适应性试验，从而能够快速识别有效患者，同时减少无效患者的暴露。同时，DNA修復抑制剂与免疫疗法、标靶治疗或传统细胞毒性药物的联合治疗策略正从探索性方案走向系统性开发路径，反映出一种向多模态治疗方法的策略调整。

2025 年关税趋势对全球药品供应链、研发进度以及 DNA 修復疗法取得策略的影响。

2025年宣布或实施的涉及关税措施的政策转变，重新引发了人们对医药原料和成品跨境供应链的关注。由于许多DNA修復疗法依赖特殊的活性成分、复杂的化学合成以及进口的实验室耗材，关税带来的成本压力可能会影响生产经济效益和临床供应的物流。为此，各公司正在重新评估供应商多元化策略，尽可能将关键生产流程迁回国内市场，并协商长期采购协议以降低价格波动。

详细的细分市场特定要求，展示了药物类别、作用机制、适应症、给药途径和最终用户趋势如何结合起来，形成独特的开发和商业化策略。

细分市场层面的洞察揭示了不同作用机制、适应症、给药途径和终端用户群中独特的研发路径和商业性考量，这些因素共同决定了投资重点。从药物类别来看，竞争格局和临床趋势涵盖了ATM抑制剂、ATR抑制剂、 DNA甲基转移酵素抑制剂、HDAC抑制剂和PARP抑制剂。在这些类别中， DNA甲基转移酵素抑制剂又可分为已上市药物和研究药物。而PARP抑制剂则构成了一个多层次的市场，包含品牌学名药和正在研发的新药，影响着定价和市场定位策略。这种多样性要求在药物生命週期的各个阶段采取差异化策略。已上市药物需要拓展适应症并累积真实世界数据（REW）；在研药物需要进行转化检验并建立策略联盟；而学名药需要采取专注于扩大市场准入和销售量的策略。

基于监管、报销和基础设施现实的区域策略差异，决定了临床开发重点和市场进入方式。

区域趋势对DNA修復疗法的研发、监管沟通和商业化等各环节的策略决策都有显着影响。在美洲，尤其註重快速与监管机构沟通、为支付方提供证据，并优先考虑主导生物标记为导向的适应症。临床试验网络和肿瘤联盟为后期评估和真实世界数据（REW）的收集提供了强大的支持。欧洲、中东和非洲（EMEA）地区的情况则更为复杂，监管协调程度不同、报销机制各异以及医疗基础设施差异较大，因此需要製定针对特定区域的市场准入计划和差异化定价策略。製造商通常会根据卫生技术评估（HTA）框架以及集中式或分散式的报销机制，优先选择这些区域内的国家进行早期上市。

为了加速推广应用，领先的研发公司正专注于以伙伴关係、诊断整合、强大的供应链和主导商业化为重点的企业策略。

DNA修復疗法领域的主要企业正展现出通用的策略性倡议：具体而言，包括建立合作伙伴关係以拓展联合治疗，投资伴随诊断研发以支持精准的患者筛选，以及开展有针对性的併购和许可活动以强化互补资产。大型製药企业正日益与生物技术公司合作，以加速转化科学发展并确保获得新型化学结构和专有生物标记平台。同时，灵活的生技公司正利用早期概念验证资料来共同开发契约，并获得III期临床试验的资金，从而建构一个以互补能力和风险共用为核心的生态系统，推动研发进展。

明确且可操作的经营团队重点，以整合生物标记主导的证据、稳健的运作和有针对性的商业化，从而推进 DNA 修復计划。

产业领导者应优先考虑一系列切实可行的倡议，将科学潜力转化为永续的商业性成功。首先，将生物标记策略和卫生经济学纳入早期研发计划，确保临床试验结果符合支付者的预期和临床决策。这将有助于申办方降低市场进入门槛，并在产品上市时提升其价值提案。其次，寻求策略联盟，将互补的作用机制和治疗方法结合，以增强联合治疗的合理性，并分散整个研发组合的风险。

采用稳健的多方法研究设计，结合专家访谈、全面的二手资讯和三角测量分析技术，以确保有效性和透明度。

本研究采用结构化、多维度的方法整合数据，结合一级资讯来源和二级资讯来源，以确保洞察的广度和深度。一手研究包括对肿瘤领域关键意见领袖（KOL）、大中小型生物製药公司高管、监管专家和市场进入负责人，从而获取关于临床开发、监管预期和商业化挑战的细緻观点。二手研究涵盖同行评审文献、临床试验註册数据、监管申报、专利趋势和公司资讯披露，并采用三角检验对研究结果进行分析，以检验战略趋势。

结论强调，协调机制创新、证据产生和营运韧性对于实现永续的临床和商业性影响至关重要。

总之，DNA修復疗法在肿瘤学领域中占据着一个至关重要且快速发展的细分市场，科学进步、临床检验和商业性实施必须协同一致，才能真正造福患者。该领域的未来不仅取决于机制创新，还取决于组织能力，例如生物标记整合、制定稳健的供应和生产策略，以及建立实现广泛应用所需的卫生经济学证据。策略伙伴关係和适应性试验设计将加速有前景的机制转化为永续的临床方案，而针对不同区域的优化上市计划将决定患者接受治疗的速度和范围。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：DNA修復药物市场：依药物类别划分

  • ATM抑制剂
  • ATR抑制剂
  • DNA甲基转移酵素酶抑制剂
  • HDAC抑制剂
  • PARP抑制剂

第九章：依作用机转分類的DNA修復药物市场

  • 单株抗体
  • 胜肽
  • 低分子化合物

第十章：DNA修復药物市场：依适应症划分

  • 乳癌
    • HER2阳性
    • 荷尔蒙受体阳性
    • 三重否定
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌

第十一章 DNA修復药物市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十二章 DNA修復药物市场：依最终用户划分

  • 医院
  • 药局
  • 专科诊所

第十三章 DNA修復药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 DNA修復药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：DNA修復药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国DNA修復药物市场

第十七章：中国DNA修復药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Artios Pharma
  • AstraZeneca PLC
  • Aurigene Discovery Technologies
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CanBas Co., Ltd.
  • Clovis Oncology
  • Corden Pharma International GmbH
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hanson Wade Group
  • Johnson & Johnson Services, Inc.
  • Merck KgaA
  • Novartis AG
  • Pfizer Inc.
  • Valerio Therapeutics
Product Code: MRR-99555D550531

The DNA Repair Drugs Market was valued at USD 9.87 billion in 2025 and is projected to grow to USD 10.53 billion in 2026, with a CAGR of 7.43%, reaching USD 16.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.87 billion
Estimated Year [2026] USD 10.53 billion
Forecast Year [2032] USD 16.31 billion
CAGR (%) 7.43%

Comprehensive orientation to the scientific advancements, regulatory context, and commercial imperatives defining DNA repair therapeutics in contemporary oncology

The DNA repair therapeutics landscape represents a convergence of molecular biology, precision oncology, and novel drug modalities that together are redefining treatment approaches for multiple tumor types. In recent years, therapies targeting DNA damage response pathways have moved from academic curiosity to clinical staples in certain indications, driven by a deeper mechanistic understanding of tumor genomics and synthetic lethality. The field now spans established classes of agents alongside emergent inhibitors that seek to exploit newly discovered vulnerabilities in cancer cells.

This introduction synthesizes the state of play for stakeholders who require a concise, authoritative orientation. It outlines the technological drivers, regulatory context, and commercial considerations shaping development priorities. By placing clinical innovation in the context of operational realities-supply chain resilience, payer engagement, and biomarker deployment-this section equips decision-makers with the baseline perspective needed to interpret subsequent, more granular analyses. Transitioning from scientific promise to routine clinical integration remains the central theme, highlighting the interplay among translational research, regulatory pathways, and commercial strategy.

How genomic precision, adaptive trials, and combination strategies are collectively reshaping development priorities and commercial models across DNA repair therapeutics

The DNA repair therapeutics ecosystem is experiencing transformative shifts that are altering R&D priorities, clinical trial design, and commercial models. Advances in genomic profiling and biomarker validation have compelled developers to design trials that are both molecularly selective and adaptive, enabling faster identification of responders while reducing exposure for non-responders. Concurrently, combination strategies that pair DNA repair inhibitors with immunotherapies, targeted agents, or conventional cytotoxics have matured from exploratory regimens into structured development paths, reflecting a strategic recalibration toward multi-modal approaches.

On the technological front, the rise of next-generation sequencing and liquid biopsy platforms has increased the feasibility of real-time patient selection and monitoring, thereby tightening the feedback loop between clinical outcomes and molecular hypotheses. From a commercial standpoint, payers and health systems are increasingly demanding demonstrable value through biomarker-defined benefit, driving sponsors to integrate health economics and outcomes research earlier in development. As a result of these intersecting forces, the landscape is evolving from single-agent, indication-focused pursuits to more nuanced, mechanism-driven portfolios that emphasize precision, combination potential, and sustainable access models.

Implications of 2025 tariff dynamics on global pharmaceutical supply chains, development timelines, and access strategies for DNA repair therapeutics

Policy shifts involving tariff measures announced or implemented in 2025 have generated renewed attention to cross-border supply chains for pharmaceutical ingredients and finished products. For DNA repair therapeutics-many of which rely on specialized active pharmaceutical ingredients, complex chemical synthesis, and imported laboratory consumables-tariff-driven cost pressures can affect manufacturing economics and the logistics of clinical supply. In response, companies are reassessing supplier diversity, onshoring critical production steps where feasible, and negotiating longer-term procurement contracts to mitigate price volatility.

Beyond immediate cost implications, tariffs interact with regulatory and commercial levers. Higher input costs can prompt adjustments to portfolio prioritization, delaying lower-priority indications or pipeline candidates that require extensive global distribution channels. In parallel, procurement and tender practices among hospitals and health systems may shift toward domestic suppliers or incumbent therapies with established supply resilience, potentially complicating market access for newer entrants dependent on international manufacturing footprints. To navigate this environment, organizations are increasing visibility into tiered supplier risk, enhancing inventory forecasting for pivotal trials, and accelerating localization strategies for manufacturing and quality control infrastructure to sustain development timelines and patient access.

Nuanced segment-driven imperatives showing how drug class, mechanism, indication, route, and end-user dynamics combine to shape distinct development and commercialization strategies

Segment-level insights reveal distinct development pathways and commercial considerations across mechanisms, indications, routes, and end users that collectively define investment priorities. By drug class, the competitive and clinical landscape spans Atm inhibitors, Atr inhibitors, Dna methyltransferase inhibitors, Hdac inhibitors, and Parp inhibitors; within these groups, Dna methyltransferase inhibitors are bifurcated between launched agents and those in the pipeline, while Parp inhibitors present a layered market of branded, generic, and pipeline entrants that influence pricing and positioning strategies. This heterogeneity necessitates differentiated lifecycle approaches: launched agents require label expansion and real-world evidence generation, pipeline candidates demand translational validation and strategic partnerships, and generics call for access and volume-driven tactics.

Considering mechanism of action, therapies based on monoclonal antibodies, peptides, and small molecules exhibit divergent development and commercialization profiles, with small molecules further subdivided into Atm, Atr, Dna methyltransferase, Hdac, and Parp inhibitor chemotypes. The modality influences dosing paradigms, manufacturing complexity, and intellectual property strategies. Indication-focused segmentation highlights breast, ovarian, pancreatic, and prostate cancers as primary therapeutic arenas, with breast cancer further resolved into Her2 positive, hormone receptor positive, and triple-negative subtypes; such granularity drives unique biomarker needs and payer narratives for each subgroup. Route of administration-intravenous, oral, and subcutaneous-affects patient adherence, clinic resource utilization, and homecare opportunities, while end user segmentation across hospitals, pharmacies, and specialty clinics shapes distribution strategies and commercial engagement models. Taken together, these intersecting segments prescribe distinct development roadmaps, go-to-market architectures, and evidence-generation priorities that innovators must reconcile when allocating finite resources.

Regional strategic differentiation across regulatory, reimbursement, and infrastructure realities that determine clinical development priorities and market access approaches

Regional dynamics materially influence strategic decision-making across development, regulatory engagement, and commercialization for DNA repair therapeutics. In the Americas, there is a pronounced emphasis on rapid regulatory engagement, payer evidence generation, and adoption pathways that favor biomarker-driven indications; clinical trial networks and oncology consortia provide a robust environment for late-stage evaluation and real-world evidence capture. Europe, Middle East & Africa present a more heterogeneous landscape where regulatory harmonization, reimbursement diversity, and variable healthcare infrastructure necessitate tailored market entry plans and differentiated pricing strategies. Manufacturers often prioritize countries within the region for early launches based on HTA frameworks and centralized or decentralized reimbursement mechanisms.

Asia-Pacific demonstrates a mix of rapid innovation adoption in select markets and infrastructure-driven constraints in others. Several countries in Asia-Pacific prioritize domestic manufacturing and local clinical data, prompting sponsors to adapt trial designs and commercial models to meet local requirements. Cross-region considerations-such as regional clinical trial enrollment strategies, supply chain routing, and localized evidence generation-play a pivotal role in shaping program timelines and access. Ultimately, regional strategies must balance the imperative for global coordination with the need to localize regulatory, clinical, and commercial approaches to achieve sustainable patient access.

Corporate strategies observed among leading developers focusing on partnerships, diagnostics integration, resilient supply chains, and evidence-driven commercialization to accelerate adoption

Leading companies in the DNA repair therapeutics domain are demonstrating a common set of strategic behaviors: forging collaborative partnerships to expand combination regimens, investing in companion diagnostic development to support precise patient selection, and deploying targeted M&A or licensing activity to shore up complementary assets. Large pharmaceutical firms are increasingly partnering with biotechs to accelerate translational science and to gain access to novel chemotypes or unique biomarker platforms. At the same time, nimble biotechnology companies are leveraging early proof-of-concept data to negotiate co-development deals or to secure capital for pivotal trials, demonstrating an ecosystem where complementary capabilities and shared risk are central to progress.

Commercially, companies are aligning external affairs, medical affairs, and market access functions earlier in development to ensure that evidence generation addresses payer needs. Supply chain resilience and localized manufacturing are emerging as strategic priorities for firms seeking to protect launch timelines against geopolitical and tariff-related headwinds. Finally, the competitive landscape is prompting companies to differentiate through real-world evidence initiatives, patient support programs, and direct engagement with specialist centers to accelerate adoption where clinical benefit is clearest. These tactics collectively reflect a shift toward more integrated, evidence-driven commercialization strategies across incumbent and emerging players alike.

Clear, implementable priorities for leadership to align biomarker-driven evidence, resilient operations, and targeted commercialization for DNA repair programs

Industry leaders should prioritize a set of actionable initiatives that translate scientific promise into durable commercial success. First, integrate biomarker strategies and health economics into early development plans so that trials generate outcomes aligned with payer expectations and clinical decision-making. By doing so, sponsors can reduce time-to-access hurdles and improve value positioning at launch. Second, pursue strategic collaborations that pair complementary mechanisms or modalities to strengthen rationale for combination regimens and to diversify risk across development portfolios.

Third, build supply chain resilience by diversifying API sources, investing in regional manufacturing capacity where justified, and establishing robust inventory planning for pivotal trials. These actions mitigate exposure to tariff shocks and logistical disruptions. Fourth, invest in companion diagnostic partnerships and real-world evidence capture to substantiate effectiveness and to support label expansion efforts. Lastly, tailor regional go-to-market approaches that account for local regulatory, reimbursement, and infrastructure nuances, and deploy targeted stakeholder engagement to accelerate guideline adoption and clinician uptake. Executing these initiatives in a coordinated fashion will improve the likelihood that promising therapeutics transition to widely accessible standards of care.

Robust multi-method research design combining expert primary interviews, comprehensive secondary sources, and triangulated analytical techniques to ensure validity and transparency

This research synthesizes data from a structured multi-method approach combining primary and secondary sources to ensure breadth and depth of insight. Primary research included interviews with key opinion leaders in oncology, executives from small and large biopharmaceutical companies, regulatory specialists, and market access professionals to capture nuanced perspectives on clinical development, regulatory expectations, and commercialization challenges. Secondary research encompassed peer-reviewed literature, clinical trial registries, regulatory filings, patent landscapes, and company disclosures to triangulate findings and validate strategic trends.

Analytical techniques applied include pipeline mapping, competitive landscaping, and scenario-based impact assessment to understand how policy, clinical, and commercial variables interact. Quality controls included source triangulation, expert validation workshops, and a documented audit trail for critical assumptions. The methodology acknowledges limitations related to evolving clinical data and policy changes, and it therefore highlights where findings are most sensitive to new trial outcomes or regulatory developments. Where possible, the analysis emphasizes reproducible methods and transparent rationale so that stakeholders can adapt the approach to their specific decision-making needs.

Concluding synthesis emphasizing the imperative to align mechanistic innovation, evidence generation, and operational resilience to achieve durable clinical and commercial impact

In conclusion, DNA repair therapeutics occupy a pivotal and rapidly evolving niche within oncology where scientific advances, clinical validation, and commercial execution must align to realize patient benefit. The sector's future will be defined not only by mechanistic innovation but also by the ability of organizations to integrate biomarkers, build resilient supply and manufacturing strategies, and generate the health-economic evidence required for broad access. Strategic partnerships and adaptive trial designs will accelerate the translation of promising mechanisms into durable clinical options, while regionally tailored launch plans will determine the speed and extent of patient uptake.

Ultimately, success in this space demands coordinated action across R&D, regulatory affairs, supply chain, and commercial functions. Stakeholders who proactively address evidence generation, payer alignment, and operational resilience will be best positioned to transform scientific opportunity into sustainable therapeutic impact for patients across the major oncology indications served by DNA repair strategies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Repair Drugs Market, by Drug Class

  • 8.1. Atm Inhibitors
  • 8.2. Atr Inhibitors
  • 8.3. Dna Methyltransferase Inhibitors
  • 8.4. Hdac Inhibitors
  • 8.5. Parp Inhibitors

9. DNA Repair Drugs Market, by Mechanism Of Action

  • 9.1. Monoclonal Antibodies
  • 9.2. Peptides
  • 9.3. Small Molecules

10. DNA Repair Drugs Market, by Indication

  • 10.1. Breast Cancer
    • 10.1.1. Her2 Positive
    • 10.1.2. Hormone Receptor Positive
    • 10.1.3. Triple Negative
  • 10.2. Ovarian Cancer
  • 10.3. Pancreatic Cancer
  • 10.4. Prostate Cancer

11. DNA Repair Drugs Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. DNA Repair Drugs Market, by End User

  • 12.1. Hospitals
  • 12.2. Pharmacies
  • 12.3. Specialty Clinics

13. DNA Repair Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. DNA Repair Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. DNA Repair Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States DNA Repair Drugs Market

17. China DNA Repair Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Artios Pharma
  • 18.6. AstraZeneca PLC
  • 18.7. Aurigene Discovery Technologies
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. CanBas Co., Ltd.
  • 18.11. Clovis Oncology
  • 18.12. Corden Pharma International GmbH
  • 18.13. Eli Lilly and Company
  • 18.14. Genentech, Inc.
  • 18.15. GlaxoSmithKline PLC
  • 18.16. Hanson Wade Group
  • 18.17. Johnson & Johnson Services, Inc.
  • 18.18. Merck KgaA
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Valerio Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA REPAIR DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA REPAIR DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 141. GCC DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. G7 DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. NATO DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)